Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis
Luo, Xiangjian1,2; Yang, Lifang1,2; Xiao, Lanbo1; Xia, Xiaofeng3; Dong, Xin1; Zhong, Juanfang1; Liu, Ying1; Li, Namei1; Chen, Ling1; Li, Hongde1; Li, Wei1; Liu, Wenbin1; Yu, Xinfang1; Chen, Hanyong4; Tang, Min1; Weng, Xinxian1; Yi, Wei1; Bode, Ann4; Dong, Zigang4; Liu, Jikai5; Cao, Ya1,2
Source PublicationONCOTARGET
AbstractGrifolin, a secondary metabolite isolated from the fresh fruiting bodies of the mushroom Albatrellus confluens, has been reported by us and others to display potent antitumor effects. However, the molecular target of grifolin has not been identified and the underlying mechanism of action is not fully understood. Here, we report that the ERK1/2 protein kinases are direct molecular targets of grifolin. Molecular modeling, affinity chromatography and fluorescence quenching analyses showed that grifolin directly binds to ERK1/2. And in vitro and ex vivo kinase assay data further demonstrated that grifolin inhibited the kinase activities of ERK1/2. We found that grifolin suppressed adhesion, migration and invasion of high-metastatic cancer cells. The inhibitory effect of grifolin against tumor metastasis was further confirmed in a metastatic mouse model. We found that grifolin decreased phosphorylation of Elk1 at Ser383, and the protein as well as the mRNA level of DNMT1 was also down-regulated. By luciferase reporter and ChIP assay analyses, we confirmed that grifolin inhibited the transcription activity of Elk1 as well as its binding to the dnmt1 promoter region. Moreover, we report that significant increases in the mRNA levels of Timp2 and pten were induced by grifolin. Thus, our data suggest that grifolin exerts its anti-tumor activity by epigenetic reactivation of metastasis inhibitory-related genes through ERK1/2-Elk1-DNMT1 signaling. Grifolin may represent a promising therapeutic lead compound for intervention of cancer metastasis, and it may also be useful as an ERK1/2 kinase inhibitor as well as an epigenetic agent to further our understanding of DNMT1 function.
KeywordGrifolin Erk1/2 Dnmt1 Metastasis
Indexed BySCI
WOS IDWOS:000369907900025
Citation statistics
Cited Times:18[WOS]   [WOS Record]     [Related Records in WOS]
Document Type期刊论文
Affiliation1.Cent S Univ, Canc Res Inst, Key Lab, Chinese Minist Educ,Xiangya Sch Med, Changsha 410078, Hunan, Peoples R China
2.Cent S Univ, Xiangya Hosp, Mol Imaging Ctr, Changsha 410078, Hunan, Peoples R China
3.Houston Methodist Res Inst, Dept Syst Med & Bioengn, Houston, TX 77030 USA
4.Univ Minnesota, Hormel Inst, Austin, MN 55912 USA
5.Chinese Acad Sci, State Key Lab Phytochem & Plant Resource West Chi, Kunming Inst Bot, Kunming 650204, Yunnan, Peoples R China
Recommended Citation
GB/T 7714
Luo, Xiangjian,Yang, Lifang,Xiao, Lanbo,et al. Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis[J]. ONCOTARGET,2015,6(40):42704-42716.
APA Luo, Xiangjian.,Yang, Lifang.,Xiao, Lanbo.,Xia, Xiaofeng.,Dong, Xin.,...&Cao, Ya.(2015).Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis.ONCOTARGET,6(40),42704-42716.
MLA Luo, Xiangjian,et al."Grifolin directly targets ERK1/2 to epigenetically suppress cancer cell metastasis".ONCOTARGET 6.40(2015):42704-42716.
Files in This Item: Download All
File Name/Size DocType Version Access License
5678-92680-2-PB.pdf(5262KB)期刊论文作者接受稿开放获取CC BY-NC-SAView Download
Related Services
Recommend this item
Usage statistics
Export to Endnote
Google Scholar
Similar articles in Google Scholar
[Luo, Xiangjian]'s Articles
[Yang, Lifang]'s Articles
[Xiao, Lanbo]'s Articles
Baidu academic
Similar articles in Baidu academic
[Luo, Xiangjian]'s Articles
[Yang, Lifang]'s Articles
[Xiao, Lanbo]'s Articles
Bing Scholar
Similar articles in Bing Scholar
[Luo, Xiangjian]'s Articles
[Yang, Lifang]'s Articles
[Xiao, Lanbo]'s Articles
Terms of Use
No data!
Social Bookmark/Share
File name: 5678-92680-2-PB.pdf
Format: Adobe PDF
All comments (0)
No comment.

Items in the repository are protected by copyright, with all rights reserved, unless otherwise indicated.